Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Case series of elranatamab for relapsed and/or refractory advanced stage AL amyloidosis finds 100% ORR and 67% CR rate; median time to heme response of 9 days (6-24), translating into cardiac and renal responses at 3-6 months.”
Title: Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory Immunoglobulin Light-Chain Amyloidosis
Authors: Pedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain, Divaya Bhutani, Shannon Miller, Annemarie Rossi, Sarah AM Cuddy, Rodney H Falk, Suzanne Lentzsch, Jacob Laubach, Giada Bianchi
You can read the Full Article in Blood.
You can find more posts featuring Robert Orlowski in OncoDaily.
